Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis

OBJECTIVE: Erlotinib plus gemcitabine is approved in Japan for the treatment of metastatic pancreatic cancer. The POLARIS surveillance study investigated safety (focusing on interstitial lung disease [ILD]) and efficacy of erlotinib plus gemcitabine in Japanese pancreatic cancer patients. METHODS: P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Jpn J Clin Oncol
Autors principals: Furuse, Junji, Gemma, Akihiko, Ichikawa, Wataru, Okusaka, Takuji, Seki, Akihiro, Ishii, Tadashi
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896695/
https://ncbi.nlm.nih.gov/pubmed/28541474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyx075
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars